Autologous hematopoietic transplantation for low-grade lymphomas

Cytotherapy

Volumn 4, Issue 3, 2002, Pages 205-215

  Gribben, John G ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

CLL; Low grade non Hodgkin's lymphoma; Mantle cell lymphoma; Stem cell transplantation

Indexed keywords

ALKYLATING AGENT; ANTINEOPLASTIC AGENT; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; LYMPHOCYTE ANTIGEN RECEPTOR;

AUTOTRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER SURVIVAL; CHEMOSENSITIVITY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; DRUG MEGADOSE; FOLLICULAR LYMPHOMA; GENE; HEMATOPOIETIC STEM CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOMODULATION; LEUKEMIA; LONG TERM CARE; LYMPHOMA; LYMPHOMA CELL; MANTLE CELL LYMPHOMA; MORBIDITY; MORTALITY; NONHODGKIN LYMPHOMA; OUTCOMES RESEARCH; PERIPHERAL BLOOD STEM CELL; POLYMERASE CHAIN REACTION; POSTOPERATIVE COMPLICATION; RELAPSE; REMISSION; REVIEW; STEM CELL TRANSPLANTATION; TREATMENT FAILURE; TUMOR CELL; ALLOTRANSPLANTATION; BONE MARROW TRANSPLANTATION; GENE TRANSLOCATION; GENETICS; IMMUNOGLOBULIN GENE; IMMUNOSUPPRESSIVE TREATMENT; MINIMAL RESIDUAL DISEASE; PATHOLOGY; RECURRENT DISEASE; RISK FACTOR;

BONE MARROW TRANSPLANTATION; CLINICAL TRIALS; GENES, IMMUNOGLOBULIN; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA; NEOPLASM, RESIDUAL; RECEPTORS, ANTIGEN; RECURRENCE; RISK FACTORS; TRANSLOCATION, GENETIC; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS;

EID: 0035995201     PISSN: 14653249     EISSN: None     Source Type: Journal    
DOI: 10.1080/146532402320219727     Document Type: Article

References (71)

1. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma
2. Natural history of and therapy for the indolent non-Hodgkin's lymphomas
3. Towards a cure in indolent lymphoproliferative diseases
4. Non-Hodgkin's lymphomas - Current status and future perspectives
5. Randomized trial of filgrastim-mobilized peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients
6. Peripheral-blood-stem-cell transplantation versus autolgous bone marrow transplantation in Hodgkin's disease and non-Hodgkin's lymphomas: A new matched-pair analysis of the European Lymphoma working party of the European Lymphoma working party of the European Group for blood and marrow transplantation
7. Randomized trial of filgrastim versus chemotherapy and filgrastim mobilization of hematopoietic progenitor cells for rescue in autologous transplantation
8. H on chromosome 14 and near a transcriptional unit on 18
9. Involvement of the bcl-2 gene in human follicular lymphoma
10. Nucleotide sequence of a t(14;18) chromosomal breakpoint in follicular lymphoma and demonstration of a breakpoint cluster region near a transcriptionally active locus on chromosome 18
11. Detection of chromosomal translocation t(14;18) within the minor cluster region of bcl-2 by polymerase chain reaction and direct genomic sequencing of the enzymatically amplified DNA in follicular lymphomas
12. Bcl-2/JH rearrangements in benign lymphoid tissues with follicular hyperplasia
13. Detection of the t(14;18) at similar frequencies in hyperplastic lymphoid tissues from American and Japanese patients
14. Lymphoma-associated translocation t(14;18) in blood B cells of normal individuals
15. Molecular cloning of the chromosomal breakpoint of B-cell lymphomas and leukemias with the t(11;14) chromosome translocation
16. Detection of the chromosomal translocation t(11;14) by polymerase chain reaction in mantle cell lymphomas
17. Antigen expression and polymerase chain reaction amplification of mantle cell lymphomas
18. High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle-cell lymphoma: No evidence for long-term remission
19. Failure of immunologic purging in mantle cell lymphoma assessed by PCR detection of minimal residual disease
20. CD5 and immunoglobulin V gene expression in B cell lymphomas and chronic lymphocytic leukemias
21. Ig VH gene expression among human follicular lymphomas
22. Clonal evolution of follicular lymphoma: Evidence for antigen selection
23. Detection by polymerase chain reaction of residual cells with the bcl-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for B-cell lymphoma
24. Eradication of polymerase chain reaction immunoglobulin gene rearrangement in non-Hodgkin's lymphoma as associated with decreased relapse after autologous bone marrow transplantation
25. Molecular monitoring of minimal residual disease in follicular and mantle cell non-Hodgkin's lymphomas treated with high-dose chemotherapy and peripheral blood progenitor cell autografting
26. Detection of cells bearing the t(14;18) translocation following myeloablative treatment and autologous bone marrow transplantation for follicular lymphoma
27. High-dose therapy with autologous bone marrow support as consolidation of remission in follicular lymphoma: Long-term clinical and molecular follow-up
28. A validated real-time quantitative PCR approach shows a correlation between tumor burden and successful ex vivo purging in follicular lymphoma patients
29. Use of paraffin wax embedded bone marrow trephine biopsy specimens as a source of archival DNA
30. Stem cell transplantation for chronic lymphocytic leukemia: Different outcome after autologous and allogeneic transplantation and correlation with minimal residual disease status
31. Autologous bone marrow transplantation in B-cell non-Hodgkin's lymphoma: Very low treatment-related mortality in 100 patients in sensitive relapse
32. Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma
33. Detection of minimal residual disease by polymerase chain reaction in B cell malignancies
34. Negative immunomagnetic ex vivo purging combined with high-dose chemotherapy with peripheral blood progenitor cell autograft in follicular lymphoma patients: Evidence for long-term clinical and molecular remissions
35. Myelodysplastic syndrome after autologous transplantation for lymphoma: The price of progress?
36. Myelodysplastic syndrome after autologous bone marrow transplantation: An additional late complication of curative cancer therapy
37. Myelodysplasia and acute myeloid leukemia occurring after autologous bone marrow transplantation for lymphoma
38. Secondary leukaemia and myelodysplasia after autografting for lymphoma: Results from the EBMT. EBMT Lymphoma and Late Effects Working Parties. European Group for Blood and Marrow Transplantation
39. High risk of therapy-related leukemia after BEAM chemotherapy and autologous stem cell transplantation for previously treated lymphomas is mainly related to primary chemotherapy and not to the BEAM-transplantation procedure
40. Secondary or therapy-related MDS and AML and their chromosome aberrations: Important to study but difficult to establish causality
41. Therapy-related acute myeloid leukemia and myelodysplasia after high-dose chemotherapy and autologous stem cell transplantation
42. Outcome in patients with myelodysplastic syndrome after autologous bone marrow transplantation for non-Hodgkin's lymphoma
43. Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: An assessment of risk factors
44. Evaluation of the risk of therapy-related MDS/AML after sutologous stem cell transplantation
45. High-dose therapy and autologous hematopoietic-cell transplantation for follicular lymphoma beyond first remission: The Stanford University experience
46. Intensive therapy with peripheral blood progenitor cell transplantation in 60 patients with poor-prognosis follicular lymphoma
47. High-dose therapy with peripheral blood progenitor cell transplantation in low-grade non-Hodgkin's lymphoma
48. Autologous bone marrow transplantation as consolidation therapy may prolong remission in newly diagnosed high-risk follicular lymphoma: A pilot study of 34 cases
49. High dose therapy and autologous bone marrow transplantation in patients with follicular lymphoma during first remission
50. Autologous stem cell transplantation for follicular lymphoma: No benefit for early transplant?
51. High-dose therapy and autologous bone marrow transplantation for follicular lymphoma in first complete or partial remission: Results of a phase II clinical trial
52. Autologous bone marrow transplantation after histologic transformation of indolent B cell malignancies
53. Autotransplants for histologically transformed follicular non-Hodgkin's lymphoma
54. High-dose therapy and autologous stem-cell support for chemosensitive transformed low-grade follicular non-Hodgkin's lymphoma: A case-matched study from the European Bone Marrow Transplant Registry
55. Efficacy of autologous stem cell transplantation in mantle cell lymphoma: A 3-year follow-up study
56. High-dose therapy with stem cell transplantation for mantle cell lymphoma: Results and prognostic factors, a single center experience
57. Autologous hematopoietic stem cell transplantation for mantle cell lymphoma
58. Intensive therapy with peripheral stem cell transplantation in 16 patients with mantle cell lymphoma
59. Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: An active regimen for aggressive mantle-cell lymphoma
60. Dexa-BEAM: An effective regimen for cytoreduction prior to high-dose chemotherapy with autologous stem cell support for patients with relapsed/refractory mantle-cell lymphoma
61. Sequential high-dose therapy and autologous stem cell transplantation for treatment of mantle cell lymphoma
62. Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: Evidence for a role of both chemotherapy and rituximab infusion
63. Autologous and allogeneic bone marrow transplantation for poor prognosis patients with B-cell chronic lymphocytic leukemia
64. Autologous and allogeneic bone marrow transplantation for chronic lymphocytic leukemia: Preliminary results
65. Allogeneic and autologous transplantation for chronic lymphocytic leukemia
66. HLA-indentical sibling bone marrow transplantation in younger patients with chronic lymphocytic leukemia. European Group for blood and marrow transplantation and the International bone marrow transplant registry
67. Interleukin-2 therapy after bone marrow or stem cell transplantation for hematologic malignancies
68. Idiotype vaccination following ABMT can stimulate specific anti-idiotype immune responses in patients with B-cell lymphoma
69. Allogeneic versus autologous bone marrow transplantation for refractory and recurrent low-grade non-Hodgkin's lymphoma
70. Allogeneic bone marrow transplantation for poor-prognosis lymphoma: Response, toxicity and survival depend on disease histology
71. Management of lymphoma recurrence after allogeneic transplantation: The relevance of graft versus lymphoma effect